On September 28, 2021, EU Scientific Committee on Consumer Safety (SCCS) released opinions open for comments on Prostaglandins/prostaglandin-analogues and Butylated Hydroxytoluene (BHT). The deadline for comments is November 23, 2021.
Opinions for Comments on Prostaglandins and Prostaglandin-analogues
Having considered the available information from published literature, the SCCS is not able to conclude on the safety of (CAS 157283-66-4) and Ethyl Tafluprostamide (CAS 1185851-52-8), when used up to the concentrations of 0.006% and 0.007% for isopropyl cloprostenate and 0.018% for ethyl tafluprostamide in cosmetics.
The SCCS has noted serious concerns about the safety of isopropyl cloprostenate and ethyl tafluprostamide when used in cosmetic products - in particular those that are intended for use in the proximity of the eye. (Click here to see the detailed concerns)
Prostaglandins and synthetic analogues are widely known to be potent pharmacologically active substances. Due to these effects, other regulatory authorities have advised against, or have prohibited, their use in eyelash growth-promoting cosmetics. In view of the potential for causing effects at very low concentrations, and the intended use in the proximity of the eye, the SCCS has noted serious concerns over the safety of prostaglandin analogues when used in cosmetic products. (Click here to see the detailed concerns)
Opinions for Comments on Butylated Hydroxytoluene (BHT)
On the basis of a safety assessment, and considering the concerns related to potential endocrine disrupting properties of BHT, the SCCS is of the opinion that BHT is safe as an ingredient up to a maximum concentration of 0.001% in mouthwash, 0.1% in toothpaste and 0.8% in other leave-on and rinse-off products.
BHT is also considered safe for a combined use of mouthwash at a concentration of 0.001%, toothpaste at a concentration of 0.1% and other leave-on and rinse-off products at the concentration of 0.8%.
(Click here to see more details)